TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high resolution. Free cash flow isn't a prominently featured metric in company ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

The put/call ratio of TXG is 0.87, indicating a bullish outlook. What are Other Shareholders Doing? ARK Investment Management holds 11,944K shares representing 11.16% ownership of the company.

The market expects 10x Genomics (TXG) to deliver a year-over-year increase ... This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor ...

ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...

10x Genomics has set its FY 2025 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link. 10x Genomics (NASDAQ:TXG – Get Free Report ...

10x Genomics (NASDAQ:TXG – Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.